Table 2a.
Risk factor | OR | Wald CI | p-value | |
---|---|---|---|---|
Sex | Male | Ref. | ||
Female | 1.337 | [0.683; 2.617] | 0.397 | |
Age | per year | 1.002 | [0.980; 1.025] | 0.858 |
BMI | per unit | 0.937 | [0.878; 1.000] | 0.051 |
Time on dialysis | per year | 0.933 | [0.874; 0.996] | 0.037 |
Number of comorbidities | per one | 0.932 | [0.562; 1.546] | 0.987 |
Hepatitis B vaccination failure | No | Ref. | ||
Yes | 1.024 | [0.491; 2.134] | 0.621 | |
IS drugs | None | Ref. | ||
At least one | 10.034 | [4.668; 21.568] | < 0.001 | |
Vaccine type | BNT162b2 mRNA | Ref. | ||
mRNA-1273 | 0.224 | [0.119; 0.421] | < 0.001 |
Ref. = reference category; T0 = before first vaccination; T2 = 8 weeks after first vaccination.
IS means immunosuppression. Comparator is the dialysis patient cohort, which shows a positive immune reaction to vaccination as defined by de novo development of any IgG-Ab or IgA-Ab against the Spike S1 subunit on T2. A negative vaccination response was defined by negative results of both above tests at T2.